Nasdaq-listed Immunovant has appointed Mark Levine as chief legal officer (CLO).
Levine was most recently general counsel and corporate secretary of Flexion Therapeutics, a commercial-stage biopharmaceutical company, where he was responsible for overseeing legal and compliance affairs related to Flexion’s 2017 launch of ZILRETTA in the US and building its pipeline. Flexion was ultimately acquired by Pacira BioSciences in late 2021.
Levine was previously general counsel and corporate secretary at Minerva Neurosciences and associate general counsel at Clinical Data. His legal experience includes advising on M&A and divestitures, licensing agreements and partnerships and development and commercialization.
Immunovant is a clinical-stage biopharmaceutical company focused on autoimmune diseases.
CEO Pete Salzmann says in a statement: ‘We are extremely pleased to welcome Mark Levine as Immunovant’s [CLO]. Mark’s broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization will enhance our existing capabilities as we plan to initiate pivotal trials for [product candidate] batoclimab in 2022.’